文献速递白血病造血干细胞移植与细胞治疗

NUP98重排儿童急性髓系白血病异基因造血干细胞移植的预后分析

[Prognostic analysis of NUP98 rearrangement in patients with pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2026-01-01

本研究回顾性分析31例接受allo-HSCT的NUP98-r儿童AML患者,中位随访35个月,3年OS率74.0%,EFS率63.9%,CIR 21.3%。移植前NUP98-r阳性者3年EFS低于阴性者,CIR高于阴性者;移植后3个月内NUP98-r阳性者均复发。

要点

  • 移植前NUP98-r阳性与更高CIR和更低EFS相关。
  • 移植后3个月内NUP98-r阳性患者后续均复发。
  • 应通过治疗使NUP98-r转阴后再行allo-HSCT。

核心结论

  • Allo-HSCT是NUP98-r pAML的有效治疗方式。
  • 移植前NUP98-r阳性与更高的CIR和更低的EFS相关。
  • 可通过治疗使NUP98-r转阴后行allo-HSCT。

研究设计与样本

  • 回顾性单臂观察性队列研究。
  • 纳入2018年4月至2024年10月在北京大学人民医院行allo-HSCT的NUP98-r pAML患者31例。
  • 收集临床特征、移植前后NUP98-r状态、复发和生存结局并分析预后影响。

主要发现

  • 31例中男16例(51.6%),女15例(48.4%),中位年龄8(2~18)岁,中位随访35(6~66)个月。
  • 最常见亚型NUP98::NSD1 22例(71.0%),其次NUP98::HOXA9 5例(16.1%);合并FLT3-ITD 18例(58.1%),WT1突变14例(45.2%)。
  • 7例移植后复发,中位复发时间6(3~48)个月。
  • 3年OS率(74.0±9.6)%,EFS率(63.9±10.1)%,CIR(21.3±8.7)%。
  • 移植前NUP98-r阴性者3年EFS(92.3±7.4)%高于阳性者(42.3±15.3)%(P=0.044);阳性者3年CIR(34.8±14.6)%高于阴性者(0)(P=0.036)。

关键数值与推荐

  • Ⅱ~Ⅳ级急性GVHD 100天累积发生率(35.4±8.6)%。
  • 慢性GVHD 3年累积发生率(64.8±9.2)%。
  • 移植后前3个月NUP98-r阳性患者后续均复发。

临床怎么用

  • 对NUP98-r pAML患者,allo-HSCT是有效治疗选择。
  • 移植前应努力通过治疗实现NUP98-r转阴以改善预后。
  • 移植后早期监测NUP98-r状态,阳性提示极高复发风险。

局限性

  • 回顾性单臂观察性研究,样本量较小(31例)。
  • 单中心研究,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To analyze the prognosis and impact of NUP98 rearrangements (NUP98-r) pre- and post-allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with pediatric acute myeloid leukemia (pAML) with NUP98-r who underwent allo-HSCT. Methods: This was a retrospective, single-arm, observational cohort study. This study enrolled patients with pAML with NUP98-r who underwent allo-HSCT at Peking University People's Hospital from April 2018 to October 2024. The clinical characteristics, NUP98-r status pre- and post-allo-HSCT, relapse, and survival outcomes of the patients were collected. The impact of NUP98-r status pre- and post-allo-HSCT on prognosis was analyzed. Results: Among 31 patients with pAML with NUP98-r who underwent allo-HSCT, 16 (51.6%) were males and 15 (48.4%) were females, with a median age of 8 years (range: 2-18 years). The median follow-up time was 35 months (range: 6-66 months). The most common NUP98-r subtype was NUP98::NSD1 (22 patients, 71.0%), followed by NUP98::HOXA9 (5 patients, 16.1%). Concurrent FLT3-ITD mutation was present in 18 patients (58.1%) and WT1 mutation in 14 patients (45.2%). Seven patients relapsed post-allo-HSCT, with a median time to relapse of 6 months (range: 3-48 months). The 100-day cumulative incidence of grade Ⅱ-Ⅳ acute graft-versus-host disease (GVHD) was (35.4±8.6) %, and the 3-year cumulative incidence of chronic GVHD was (64.8±9.2) %. The 3-year overall survival, event-free survival (EFS), and cumulative incidence of relapse (CIR) rates were (74.0±9.6) %, (63.9±10.1) %, and (21.3±8.7) %, respectively. The 3-year EFS was higher in patients who were negative for NUP98-r pre-allo-HSCT [ (92.3±7.4) %] than in those positive for NUP98-r [ (42.3± 15.3) %] (P=0.044). The 3-year CIR was higher in patients positive for NUP98-r pre-allo-HSCT [ (34.8±14.6) %] than in those negative for NUP98-r (0) (P=0.036). All patients who were positive for NUP98-r within the first 3 months post-allo-HSCT subsequently relapsed. Conclusion: Allo-HSCT is an effective method for treating NUP98-r pAML, and NUP98-r positivity pre-allo-HSCT is associated with higher CIR and lower EFS. Therefore, efforts should be made to achieve a negative NUP98-r status through treatment before undergoing allo-HSCT. 目的: 分析核孔蛋白98重排(NUP98-r)儿童急性髓系白血病(pAML)患者行异基因造血干细胞移植(allo-HSCT)的预后及allo-HSCT前后NUP98-r对预后的影响。 方法: 本研究为回顾性单臂观察性队列研究。纳入2018年4月至2024年10月在北京大学人民医院行allo-HSCT的NUP98-r pAML患者,收集其临床特征、allo-HSCT前后NUP98-r情况、复发和生存结局,并分析allo-HSCT前后NUP98-r对预后的影响。 结果: 31例行allo-HSCT的NUP98-r pAML患者中,男16例(51.6%),女15例(48.4%),中位年龄8(2~18)岁,中位随访时间35(6~66)个月。最常见的NUP98-r亚型为NUP98::NSD1(22例,71.0%),其次为NUP98::HOXA9(5例,16.1%)。18例(58.1%)合并FLT3-ITD突变,14例(45.2%)合并WT1突变。7例患者allo-HSCT后复发,复发中位时间6(3~48)个月。Ⅱ~Ⅳ级急性移植物抗宿主病100 d累积发生率为(35.4±8.6)%,慢性移植物抗宿主病3年累积发生率为(64.8±9.2)%。3年总生存(OS)率、无事件生存(EFS)率和累积复发率(CIR)分别为(74.0±9.6)%、(63.9±10.1)%、(21.3±8.7)%。allo-HSCT前NUP98-r阴性患者的3年EFS率高于NUP98-r阳性患者[(92.3±7.4)%对(42.3±15.3)%,P=0.044],NUP98-r阳性患者的3年CIR高于NUP98-r阴性患者[(34.8±14.6)%对0,P=0.036]。allo-HSCT后前3个月NUP98-r阳性的患者后续均复发。 结论: allo-HSCT是NUP98-r pAML有效的治疗方式,且allo-HSCT前NUP98-r阳性与更高的CIR和更低的EFS率相关,可通过治疗使NUP98-r转阴后行allo-HSCT。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Wang HF, Hu GH, Bai L, et al. [Prognostic analysis of NUP98 rearrangement in patients with pediatric acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation]. Zhonghua Xue Ye Xue Za Zhi. 2026. PMID: 42409734. doi:10.3760/cma.j.cn121090-20251109-00515

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。